Company profile
Sciwind Biosciences
Peptide therapeutics (obesity/metabolic)
Privately held: no public share price · China
Assets
(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GLP-1 receptorPeptide | Obesity | |
| Phase 3 | GLP-1 receptorPeptide | Obesity | |
| Phase 1 | GLP-1 receptorSmall molecule | Type 2 Diabetes |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.